Tocilizumab: what can we expect from this drug in the fight against Covid-19?

Audio 06:48

One of the advantages of this drug is that it is already available in hospitals, says Professor Gottenberg. REUTERS / Pascal Rossignol

By: Andréane Meslard

Rare glimmer of hope in the crisis: a drug, the immunomodulator tocilizumab, has shown its effectiveness in preventing serious forms of pneumonia from Covid-19, according to a French study not yet published, the first results of which were revealed Monday by the AP-HP. This medication, usually used in the treatment of rheumatoid arthritis, had less need for respiratory assistance and had a lower death rate during the 14 days of follow-up. RFI interviewed Professor Jacques-Eric Gottenberg, head of the rheumatology department at the CHU Strasbourg-Hautepierre.

  • Coronavirus
  • Health and Medicine

On the same subject

Decryption

Covid: before a treatment or a vaccine, should we focus on group immunity?

Little and big history of epidemics

The medicine that was to save Africa